Metabolic improvement of poorly controlled noninsulin-dependent diabetes mellitus decreases bone turnover

被引:112
作者
Okazaki, R
Totsuka, Y
Hamano, K
Ajima, M
Miura, M
Hirota, Y
Hata, K
Fukumoto, S
Matsumoto, T
机构
[1] KANTO TEISHIN HOSP, DEPT METAB & ENDOCRINOL, TOKYO, JAPAN
[2] UNIV TOKYO, SCH MED, DEPT INTERNAL MED 4, TOKYO 113, JAPAN
[3] UNIV TOKUSHIMA, SCH MED, DEPT INTERNAL MED 1, TOKUSHIMA 770, JAPAN
关键词
D O I
10.1210/jc.82.9.2915
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Patients with poorly controlled noninsulin dependent diabetes mellitus (NIDDM) are shown to have higher bone mass. However, the influence of changes in glycemic control on bone turnover is not known. To clarify whether metabolic improvement of poorly controlled NIDDM affects bone turnover, markers for glucose, mineral, and bone metabolism were assessed before and after glycemic control for 3 weeks in 78 poorly controlled NIDDM patients with initial hemoglobin Ale over 8%. Metabolic improvement caused a reduction in urinary calcium (Ca) and phosphate (Pi) and serum 1,25(OH)(2)D levels, and an increase in serum Pi without changes in serum Ca or parathyroid hormone levels. Bone resorption markers, urinary deoxypyridinoline (Dpd) and type I collagen carboxy-terminal telopeptide (CTx), as well as a bone formation marker, serum bone type alkaline phosphatase (BALP), were reduced. However, another bone formation marker, serum osteocalcin (OC), was low before treatment and was elevated after treatment. The decrease in Dpd, CTx and BALP, but not the increase in OC, correlated with each other and with the improvement in glycemic indices. In conclusion, metabolic improvement of poorly controlled NIDDM decreases bone turnover within a short period. Thus, glycemic control may protect NIDDM patients from bone loss. It is possible that serum OC is affected by hyperglycemia per se, and may not correctly reflect bone turnover.
引用
收藏
页码:2915 / 2920
页数:6
相关论文
共 34 条
[1]  
AMER DIABET ASSOC, 1993, DIABETES, V42, P1555
[2]  
BARRETTCONNOR E, 1992, JAMA-J AM MED ASSOC, V268, P3333
[3]   DIABETIC OSTEOMYELOPATHY - HISTO-BIOPTIC DATA OF BONE AND BONE-MARROW IN DIABETES-MELLITUS [J].
BARTL, R ;
MOSER, W ;
BURKHARDT, R ;
SANDEL, P ;
KAMKE, W ;
MAHR, G ;
ADELMANN, BC .
KLINISCHE WOCHENSCHRIFT, 1978, 56 (15) :743-754
[4]   FACTORS ASSOCIATED WITH APPENDICULAR BONE MASS IN OLDER WOMEN [J].
BAUER, DC ;
BROWNER, WS ;
CAULEY, JA ;
ORWOLL, ES ;
SCOTT, JC ;
BLACK, DM ;
TAO, JL ;
CUMMINGS, SR .
ANNALS OF INTERNAL MEDICINE, 1993, 118 (09) :657-665
[5]   INFLUENCE OF AGE, SEX, AND INSULIN ON OSTEOBLAST FUNCTION - OSTEOBLAST DYSFUNCTION IN DIABETES-MELLITUS [J].
BOUILLON, R ;
BEX, M ;
VANHERCK, E ;
LAUREYS, J ;
DOOMS, L ;
LESAFFRE, E ;
RAVUSSIN, E .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 1995, 80 (04) :1194-1202
[6]  
Christiansen C, 1990, Osteoporos Int, V1, P35, DOI 10.1007/BF01880414
[7]  
DELEEUW I, 1976, DIABETOLOGIA, V12, P385
[8]   AN EVALUATION OF BONE-DENSITY AND TURNOVER IN PREMENOPAUSAL WOMEN WITH TYPE-1 DIABETES-MELLITUS [J].
GALLACHER, SJ ;
FENNER, JAK ;
FISHER, BM ;
QUIN, JD ;
FRASER, WD ;
LOGUE, FC ;
COWAN, RA ;
BOYLE, IT ;
MACCUISH, AC .
DIABETIC MEDICINE, 1993, 10 (02) :129-133
[9]   MINERAL METABOLISM IN DIABETES-MELLITUS - CHANGES ACCOMPANYING TREATMENT WITH A PORTABLE SUBCUTANEOUS INSULIN INFUSION SYSTEM [J].
GERTNER, JM ;
TAMBORLANE, WV ;
HORST, RL ;
SHERWIN, RS ;
FELIG, P ;
GENEL, M .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 1980, 50 (05) :862-866
[10]  
GUNDBERG CM, 1986, J BIOL CHEM, V261, P4557